Is WuXi AppTec Co., Ltd. a good investment? WuXi AppTec Co., Ltd. (603259.SS) is currently trading at 144.41 CNY. Market analysts have a consensus price target of 202.34 CNY. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 16.80. This valuation is generally in line with the broader market.
Earnings Schedule: WuXi AppTec Co., Ltd. is expected to release its next earnings report on March 22, 2027. The market consensus estimate for Forward EPS is 10.17.
For income investors, WuXi AppTec Co., Ltd. pays a dividend yield of 1.43%. With a payout ratio of 28%, the dividend appears sustainable.
Yes, it pays an annual dividend of 2.09 CNY (1.43% yield).
WuXi AppTec Co., Ltd. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
The next earnings date is projected to be March 22, 2027. The company currently has a trailing EPS of 8.71.
WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs in the People's Republic of China, the United States, Europe, and internationally. The company operates through WuXi Chemistry, WuXi Testing, WuXi Biology, and Others segments. It offers contract research, development, and manufacturing organization (CDRMO) services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions which support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. The company also provides laboratory testing services, such as toxicology, DMPK, and bioanalytical services; clinical contract research organization services, including Phase I to Phase IV clinical development services, and bioequivalence for products including pharmaceuticals and biologics; and site management organization, patient recruitment, site start-up, and academic research organization. In addition, it offers services for biology; CDRMO platform for small molecules, oligonucleotides, and peptides; drug research and development testing; and clinical research services. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People's Republic of China.
| Year | Total Dividends |
|---|---|
| ▸2027 |
2.09 CNY
|
| Sept. 6, 2027 (estimated) | 0.5100 |
| May 21, 2027 (estimated) | 1.5793 |
| ▸2026 |
2.09 CNY
|
| Sept. 4, 2026 | 0.5100 |
| May 29, 2026 | 1.5793 |
| ▸2025 |
3.01 CNY
|
| Sept. 26, 2025 | 0.3500 |
| May 21, 2025 | 0.9817 |
| May 21, 2025 | 0.3500 |
| May 21, 2025 | 1.3317 |
| ▸2024 |
0.99 CNY
|
| June 26, 2024 | 0.9897 |
| ▸2023 |
0.89 CNY
|
| June 14, 2023 | 0.8927 |
| ▸2022 |
0.52 CNY
|
| June 9, 2022 | 0.5174 |
| ▸2021 |
0.36 CNY
|
| June 8, 2021 | 0.3630 |
| ▸2020 |
0.34 CNY
|
| June 4, 2020 | 0.3370 |
| ▸2019 |
0.58 CNY
|
| July 2, 2019 | 0.5800 |
| Name | Payment Date | Status | Amount |
|---|---|---|---|
| WuXi AppTec Co., Ltd. | Sep 04, 2026 | Paid | 0.51 CNY |
| WuXi AppTec Co., Ltd. | May 29, 2026 | Paid | 1.57927 CNY |
| Split Date | Split Ratio to 1 |
|---|---|
| July 2, 2019 | 1.4 |
| June 4, 2020 | 1.4 |
| June 8, 2021 | 1.2 |
Community Discussion